181 related articles for article (PubMed ID: 10954203)
1. Modulation of urokinase-type and tissue-type plasminogen activator occurs at an early stage of progressing stages of chronic venous insufficiency.
Peschen M; Rogers AA; Chen WY; Vanscheidt W
Acta Derm Venereol; 2000 May; 80(3):162-6. PubMed ID: 10954203
[TBL] [Abstract][Full Text] [Related]
2. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
[TBL] [Abstract][Full Text] [Related]
3. Severity of venous insufficiency is related to the density of microvascular deposition of PAI-1, uPA and von Willebrand factor.
Kolbach DN; Hamulyák K; Prins MH; Neumann HA; Cleutjens JP
Vasa; 2004 Feb; 33(1):19-24. PubMed ID: 15061043
[TBL] [Abstract][Full Text] [Related]
4. Expression of tissue-type and urokinase-type plasminogen activator activities in chronic venous leg ulcers.
Rogers AA; Burnett S; Lindholm C; Bjellerup M; Christensen OB; Zederfeldt B; Peschen M; Chen WY
Vasa; 1999 May; 28(2):101-5. PubMed ID: 10409920
[TBL] [Abstract][Full Text] [Related]
5. Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers.
Stacey MC; Burnand KG; Mahmoud-Alexandroni M; Gaffney PJ; Bhogal BS
Br J Surg; 1993 May; 80(5):596-9. PubMed ID: 8518896
[TBL] [Abstract][Full Text] [Related]
6. The role of the urokinase-type plasminogen activator (uPA) and its receptor (CD87) in lipodermatosclerosis.
Herouy Y; Aizpurua J; Stetter C; Dichmann S; Idzko M; Hofmann C; Gitsch G; Vanscheidt W; Schöpf E; Norgauer J
J Cutan Pathol; 2001 Jul; 28(6):291-7. PubMed ID: 11401675
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activation in venous leg ulcers.
Herouy Y; Trefzer D; Hellstern MO; Stark GB; Vanscheidt W; Schöpf E; Norgauer J
Br J Dermatol; 2000 Nov; 143(5):930-6. PubMed ID: 11069499
[TBL] [Abstract][Full Text] [Related]
8. Expression of the adhesion molecules ICAM-1, VCAM-1, LFA-1 and VLA-4 in the skin is modulated in progressing stages of chronic venous insufficiency.
Peschen M; Lahaye T; Hennig B; Weyl A; Simon JC; Vanscheidt W
Acta Derm Venereol; 1999 Jan; 79(1):27-32. PubMed ID: 10086854
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activators, venous leg ulcers and reepithelialization.
Lotti T; Benci M
Int J Dermatol; 1995 Oct; 34(10):696-9. PubMed ID: 8537156
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis of corneal epithelial defects: role of plasminogen activator.
Hayashi K; Berman M; Smith D; el-Ghatit A; Pease S; Kenyon KR
Curr Eye Res; 1991 May; 10(5):381-98. PubMed ID: 1909616
[TBL] [Abstract][Full Text] [Related]
11. Expression of plasminogen activator enzymes in psoriatic epidermis.
Spiers EM; Lazarus GS; Lyons-Giordano B
J Invest Dermatol; 1994 Mar; 102(3):333-8. PubMed ID: 8120416
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous findings in patients with chronic venous insufficiency.
Kılınç F; Akbaş A; Şener S; Hayran Y; Aktaş A
J Cosmet Dermatol; 2022 May; 21(5):2106-2112. PubMed ID: 34240795
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
Lund LR; Green KA; Stoop AA; Ploug M; Almholt K; Lilla J; Nielsen BS; Christensen IJ; Craik CS; Werb Z; Danø K; Rømer J
EMBO J; 2006 Jun; 25(12):2686-97. PubMed ID: 16763560
[TBL] [Abstract][Full Text] [Related]
14. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
Iyer AM; Zurolo E; Boer K; Baayen JC; Giangaspero F; Arcella A; Di Gennaro GC; Esposito V; Spliet WG; van Rijen PC; Troost D; Gorter JA; Aronica E
Neuroscience; 2010 May; 167(3):929-45. PubMed ID: 20219643
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of platelet-derived growth factor receptor alpha and beta and vascular endothelial growth factor in the skin of patients with chronic venous insufficiency.
Peschen M; Grenz H; Brand-Saberi B; Bunaes M; Simon JC; Schöpf E; Vanscheidt W
Arch Dermatol Res; 1998 Jun; 290(6):291-7. PubMed ID: 9705159
[TBL] [Abstract][Full Text] [Related]
16. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
17. Growth factors, tissue and urokinase-type plasminogen activators in venous ulcers.
Lagattolla NR; Stacey MC; Burnand KG; Gaffney PG
Ann Cardiol Angeiol (Paris); 1995; 44(6):299-303. PubMed ID: 7574362
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator modulates mammalian circadian clock phase regulation in tissue-type plasminogen activator knockout mice.
Cooper JM; Rastogi A; Krizo JA; Mintz EM; Prosser RA
Eur J Neurosci; 2017 Mar; 45(6):805-815. PubMed ID: 27992087
[TBL] [Abstract][Full Text] [Related]
19. Expression of urokinase-type plasminogen activator and its receptor during ovarian follicular development.
Li M; Karakji EG; Xing R; Fryer JN; Carnegie JA; Rabbani SA; Tsang BK
Endocrinology; 1997 Jul; 138(7):2790-9. PubMed ID: 9202219
[TBL] [Abstract][Full Text] [Related]
20. [Pathogenesis of skin pathologic changes and ulceration].
Qian HS
Zhonghua Yi Xue Za Zhi; 1993 Jun; 73(6):352-4, 381-2. PubMed ID: 8258106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
